Dashboard
Manage Tickers

OCGNOcugen, Inc.

Nasdaq ocugen.com


$ 1.62 $ 0.11 (7.28 %)    

Monday, 01-Jul-2024 15:13:18 EDT
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 481.74 $ 1.45 (0.3 %)
DIA $ 391.28 $ -0.81 (-0.21 %)
SPY $ 545.14 $ -0.27 (-0.05 %)
TLT $ 89.94 $ -0.47 (-0.51 %)
GLD $ 215.51 $ 0.37 (0.17 %)
$ 1.55
$ 1.51
$ 1.61 x 6,200
$ 1.63 x 482
$ 1.49 - $ 1.64
$ 0.35 - $ 2.11
42,033,421
na
398.71M
$ 1.85
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 05-14-2024 03-31-2024 10-Q
2 04-16-2024 12-31-2023 10-K
3 11-09-2023 09-30-2023 10-Q
4 08-21-2023 06-30-2023 10-Q
5 05-05-2023 03-31-2023 10-Q
6 02-28-2023 12-31-2022 10-K
7 11-08-2022 09-30-2022 10-Q
8 08-05-2022 06-30-2022 10-Q
9 05-06-2022 03-31-2022 10-Q
10 02-28-2022 12-31-2021 10-K
11 11-09-2021 09-30-2021 10-Q
12 08-06-2021 06-30-2021 10-Q
13 05-07-2021 03-31-2021 10-Q
14 03-19-2021 12-31-2020 10-K
15 11-06-2020 09-30-2020 10-Q
16 08-14-2020 06-30-2020 10-Q
17 05-08-2020 03-31-2020 10-Q
18 03-27-2020 12-31-2019 10-K
19 11-12-2019 09-30-2019 10-Q
20 08-09-2019 06-30-2019 10-Q
21 05-15-2019 03-31-2019 10-Q
22 03-22-2019 12-31-2018 10-K
23 11-08-2018 09-30-2018 10-Q
24 08-09-2018 06-30-2018 10-Q
25 05-10-2018 03-31-2018 10-Q
26 03-15-2018 12-31-2017 10-K
27 11-09-2017 09-30-2017 10-Q
28 08-10-2017 06-30-2017 10-Q
29 05-11-2017 03-31-2017 10-Q
30 03-16-2017 12-31-2016 10-K
31 11-10-2016 09-30-2016 10-Q
32 08-11-2016 06-30-2016 10-Q
33 05-12-2016 03-31-2016 10-Q
34 03-10-2016 12-31-2015 10-K
35 11-12-2015 09-30-2015 10-Q
36 08-12-2015 06-30-2015 10-Q
37 05-14-2015 03-31-2015 10-Q
38 03-27-2015 12-31-2014 10-K
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

ocugen-discloses-data-and-safety-monitoring-board-approves-enrollment-in-high-dose-cohort-3-in-gardian-study-for-stargardt-disease-company-says-it-established-medium-dose-as-safe-and-tolerable-dose-in-current-ocu410st-clinical-trial
Ocugen Discloses Data And Safety Monitorin...
06/21/2024 11:05:41

Six patients with Stargardt disease have been dosed in the Phase 1/2 clinical trial to date in the low dose cohort and medium d...

ocugen-begins-phase-3-trial-for-gene-therapy-to-treat-retinitis-pigmentosa
Ocugen Begins Phase 3 Trial for Gene Thera...
06/20/2024 10:32:16

Ocugen, Inc. ("Ocugen" or the "Company") (NASDAQ:OCGN), a biotechnology company focused on discovering, develop...

vanda-pharmaceuticals-and-other-big-stocks-moving-lower-in-thursdays-pre-market-session
Vanda Pharmaceuticals And Other Big Stocks...
06/20/2024 09:29:09

ocgn---analyzing-ocugens-short-interest
(OCGN) - Analyzing Ocugen's Short Interest
05/31/2024 15:30:27

ocugen-announces-data-and-safety-monitoring-board-has-recommended-to-proceed-with-dosing-subsequent-ga-subjects-with-low-dose-of-ocu410-in-dose-expansion-phase-and-concurrently-initiate-phase-2-dosing
Ocugen Announces Data And Safety Monitorin...
05/31/2024 12:39:26

dxc-technology-issues-weak-outlook-joins-take-two-interactive-and-other-big-stocks-moving-lower-in-fridays-pre-market-session
DXC Technology Issues Weak Outlook, Joins ...
05/17/2024 09:34:01

nayax-posts-weak-q1-results-joins-gamestop-iris-energy-and-other-big-stocks-moving-lower-in-thursdays-pre-market-session
Nayax Posts Weak Q1 Results, Joins GameSto...
05/16/2024 09:40:17

chardan-capital-maintains-buy-on-ocugen-maintains-5-price-target
Chardan Capital Maintains Buy on Ocugen, M...
05/15/2024 14:57:56

Chardan Capital analyst Daniil Gataulin maintains Ocugen (NASDAQ:OCGN) with a Buy and maintains $5 price target.

4-analysts-assess-ocugen-what-you-need-to-know
4 Analysts Assess Ocugen: What You Need To...
05/15/2024 12:01:09

hc-wainwright--co-reiterates-buy-on-ocugen-maintains-7-price-target
HC Wainwright & Co. Reiterates Buy on Ocug...
05/15/2024 10:45:47

HC Wainwright & Co. analyst Swayampakula Ramakanth reiterates Ocugen (NASDAQ:OCGN) with a Buy and maintains $7 price tar...

ocugen-completed-dosing-in-the-second-cohort-of-its-phase-12-gardian-clinical-trial-for-ocu410st-aav-hrora-a-modifier-gene-therapy-candidate-for-stargardt-disease-as-a-one-time-treatment
Ocugen Completed Dosing In The Second Coho...
05/15/2024 10:35:41

ocugen-q1-2024-gaap-eps-005-beats-006-estimate-sales-1014m-up-from-443000k-yoy
Ocugen Q1 2024 GAAP EPS $(0.05) Beats $(0....
05/14/2024 11:03:15

why-perficient-shares-are-trading-higher-by-around-53-here-are-20-stocks-moving-in-mondays-mid-day-session
Why Perficient Shares Are Trading Higher B...
05/06/2024 16:32:34

Core News & Articles
Why Clever Leaves Holdings Shares Are Trad...
04/29/2024 17:04:01

ocugen-announces-ocu400-modifier-gene-therapy-phase-12-data-presentation-at-retinal-cell-and-gene-therapy-innovation-summit-2024
Ocugen Announces OCU400, Modifier Gene The...
04/29/2024 10:47:57

Ocugen, Inc. (Ocugen or the Company) (NASDAQ:OCGN), a biotechnology company focused on discovering, developing, and commerciali...

ocugen-says-it-will-present-on-modifier-gene-therapy-platform-at-association-for-research-in-vision-and-ophthalmology-2024-annual-meeting
Ocugen Says It Will Present On Modifier Ge...
04/26/2024 10:36:41

alphabet-to-rally-around-14-here-are-10-top-analyst-forecasts-for-monday
Alphabet To Rally Around 14%? Here Are 10 ...
04/22/2024 12:32:56

key-takeaways-from-ocugen-analyst-ratings
Key Takeaways From Ocugen Analyst Ratings
04/22/2024 12:01:19

chardan-capital-maintains-buy-on-ocugen-raises-price-target-to-5
Chardan Capital Maintains Buy on Ocugen, R...
04/22/2024 11:47:17

Chardan Capital analyst Daniil Gataulin maintains Ocugen (NASDAQ:OCGN) with a Buy and raises the price target from $4 to $5.

ocugen-says-it-has-completed-dosing-of-subjects-with-geographic-atrophy-in-cohort-2-of-phase-12-armada-clinical-trial-of-ocu410a-modifier-gene-therapy
Ocugen Says It Has Completed Dosing of Sub...
04/19/2024 11:15:36

Company announced that dosing is complete in the second cohort of its Phase 1/2 ArMaDa clinical trial for OCU410 (AAV-hRORA)—a ...

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

07/01/2024 Globe Life Inc. f/k/a Torchmark Corporation (GL)
07/01/2024 Equinix, Inc. (EQIX)
07/02/2024 Intel Corporation (INTC)
07/05/2024 AXT, Inc. (AXTI)
07/05/2024 Altimmune, Inc. (ALT)
07/09/2024 Li Auto Inc. (LI)
07/12/2024 Inari Medical, Inc. (NARI)
07/12/2024 Sprout Social, Inc. (SPT)
07/15/2024 UnitedHealth Group Inc. (UNH)
07/16/2024 Teladoc Health, Inc. (TDOC)

NEW CASE INVESTIGATION

Ooma Inc (OOMA) AnaptysBio Inc (ANAB)